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ABSTRACT
Cells secrete extracellular RNA (exRNA) to their surrounding environment and exRNA has been found in
many body ﬂuids such as blood, breast milk and cerebrospinal ﬂuid. However, there are conﬂicting results
regarding the nature of exRNA. Here, we have separated 2 distinct exRNA proﬁles released by mast cells,
here termed high-density (HD) and low-density (LD) exRNA. The exRNA in both fractions was characterized
by microarray and next-generation sequencing. Both exRNA fractions contained mRNA and miRNA, and
the mRNAs in the LD exRNA correlated closely with the cellular mRNA, whereas the HD mRNA did not.
Furthermore, the HD exRNA was enriched in lincRNA, antisense RNA, vault RNA, snoRNA, and snRNA with
little or no evidence of full-length 18S and 28S rRNA. The LD exRNA was enriched in mitochondrial rRNA,
mitochondrial tRNA, tRNA, piRNA, Y RNA, and full-length 18S and 28S rRNA. The proteomes of the HD and
LD exRNA-containing fractions were determined with LC-MS/MS and analyzed with Gene Ontology term
ﬁnder, which showed that both proteomes were associated with the term extracellular vesicles and
electron microscopy suggests that at least a part of the exRNA is associated with exosome-like
extracellular vesicles. Additionally, the proteins in the HD fractions tended to be associated with the
nucleus and ribosomes, whereas the LD fraction proteome tended to be associated with the
mitochondrion.
We show that the 2 exRNA signatures released by a single cell type can be separated by ﬂoatation on a
density gradient. These results show that cells can release multiple types of exRNA with substantial
differences in RNA species content. This is important for any future studies determining the nature and
function of exRNA released from different cells under different conditions.
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Introduction
Extracellular nucleic acids (cell-free nucleic acids) were discov-
ered in the late 1960s/early 1970s in serum/plasma and synovial
ﬂuid.1-3 Since then, their potential use as biomarkers for several
different pathological conditions has been investigated, including
diseases such as cancer, cardiovascular disease, pre-eclampsia,
and autoimmune disease.4-7 Extracellular circulating DNA (cell-
free DNA; cfDNA) is considered to be a result of apoptosis of
lymphocytes and blood cells in healthy individuals, but it can
also originate from tumors in cancer patients.8 The cfDNA is
usually unprotected and can be degraded quickly by circulating
DNases. Extracellular RNA (exRNA) is not intrinsically resistant
to endogenous RNase activity,9,10 and it can be selectively
released by viable cells as cargo inside extracellular vesicles (EVs)
or within protective high density lipoproteins (HDLs) or protein
complexes.9,11,12 When protected by a lipid bilayer or a protein,
the exRNA can evade degradation by circulating RNases.
EVs (including apoptotic bodies, microvesicles, and exo-
somes) are released by most human cells and can shuttle
molecules such as proteins, RNA, and lipids from one cell
to another, thereby inﬂuencing the recipient cell phenotype.
This ﬁeld is currently growing very rapidly, and it has vast
implications for understanding cell-to-cell communication
in different diseases, including cancer.13-17 Also, EVs and
EV cargo have the potential to be used as biomarkers in
disease and as gene vectors for therapeutic nucleotide deliv-
ery.18-20 EVs have been shown to contain mRNA and
miRNA as well as several non-coding RNA (ncRNA) classes
such as small nucleolar RNAs (snoRNA), piwi-interacting
RNA (piRNA), vault RNA, Y RNA, and tRNA.21 Subpopu-
lations of EVs have been shown to contain different miRNA
signatures22 and breast cancer cells release miRNA both
non-selectively in large vesicles and selectively in smaller
vesicles.23
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The non-vesicle-associated exRNA is associated with and
protected by protein complexes, including argonaute 2 and
nucleophosmin 19,10,24 or HDLs.11,25 Until now, protein com-
plexes and HDL have only been demonstrated to contain
miRNA9-11,24 but not mRNA10,11 or other ncRNA classes.
Because HDLs have an average size of 8–12 nm, and are there-
fore considerably smaller than EVs that are 50–5000 nm in
diameter, it is not surprising that the diversity of their RNA
cargo is smaller.
However, conﬂicting results regarding the nature of exRNA
has been suggested. In the current study, we hypothesized that
cells release different exRNA signatures, one consisting of full-
length rRNA that can be seen as distinct peaks on an electro-
pherogram and one that does not consist of full-length rRNA,
and therefore do not show rRNA peaks. We therefore separated
2 distinct exRNA proﬁles from the human mast cell line HMC-
1 by their buoyant density. Brieﬂy, we ﬁrst discard microve-
sicles and apoptotic bodies and then used centrifugation and
density gradient isolation procedures to separate the 2 exRNA
proﬁles. The exRNA was determined with both microarray
(miRNA and mRNA) and next-generation sequencing (NGS;
all types of coding and ncRNA classes). The exRNA-associated
proteins were determined with LC-MS/MS, Western blot, and
ﬂow cytometry.
Results
Detection of 2 distinct extracellular RNA proﬁles
Cells, apoptotic bodies, and cellular debris were removed from
the cell culture media by 300 £ g and 16,500 £ g centrifuga-
tions. Both ﬁltered (0.2 mm) and non-ﬁltered supernatants
were then ultracentrifuged at 120,000 £ g. Pellets collected after
the 120,000 £ g ultracentrifugation were further separated on a
density gradient (schematics are shown in Fig. S1A). Ten frac-
tions were collected and washed from each sucrose gradient
before their RNA proﬁle was analyzed with a Bioanalyzer.
Based on the RNA proﬁles of the different fractions, it could be
concluded that 2 distinct exRNA signatures were present in the
cell supernatant, one containing peaks for full-length rRNA
and the other one not containing such peaks (Fig. S1B). The
ﬁrst exRNA proﬁle was collected from fractions 8–10 (density
1.24–1.31 g/cm3), and will hereafter be called high-density
(HD) exRNA. The second exRNA proﬁle was collected from
fractions 2–6 (density 1.09–1.21 g/cm3) and will hereafter be
called low-density (LD) exRNA. The RNAs detected in the HD
fractions showed a relatively broad peak for short RNAs (25–
500 nucleotides) and no prominent rRNA peaks (Fig. 1A),
whereas the RNA detected in the LD fractions had a signiﬁ-
cantly narrower peak for the short RNAs (50–150 nucleotides)
and showed distinct 18S and 28S rRNA peaks (Fig. 1B). These
results demonstrate that the exRNA must be associated with
other molecules/structures because free RNA has a density of
1.6–1.9 g/cm3 26 and the exRNA without the 18S and 28S
rRNA peaks from the HD fractions are associated with struc-
tures that have a higher density than the structures associated
with the rRNA-positive exRNA in the LD fractions. Therefore,
a density gradient can be used to separate and purify these dif-
ferent exRNA-associated structures.
Validation of these ﬁndings was performed by loading the
isolated pellets on the top of the sucrose gradient, which
resulted in a similar distribution of RNA proﬁles as the bot-
tom-loaded gradients, showing that the exRNA-associated
structures reach their equilibrium buoyant density after the
performed centrifugation (Fig. S2A). The distribution of
exRNA with or without full-length rRNA peaks was also con-
ﬁrmed in an erythropoietic cell line, TF1 (Fig. S2B), showing
that these 2 distinct exRNA proﬁles are not exclusive for mast
cells.
The exRNA in the high- and low-density fractions have
different miRNA and mRNA contents as determined by
microarray
Because the exRNA proﬁles for the HD and LD fractions were
substantially different (Fig. 1A and B), both the miRNA and
mRNA contents of the HD and LD fractions were determined
by 3D-GeneTM microarray technology (Toray Industries, Inc.)
in multiple biological replicates of both fractions. The miRNA
and mRNA contents were also determined in the exRNA-
producing cells. Principal component analysis (PCA) showed
that the biological replicates of RNA samples from the cells and
the HD and LD fractions formed distinct and separate clusters
for both miRNA and mRNA (Fig. 1C and D). The reproducibil-
ity was further supported by a positive correlation of RNA
expression among the biological replicates (Fig. S3A and B).
A total of 3311, 4985, and 9836 mRNAs were identiﬁed in all
HD, all LD, and all cellular samples, respectively (Tables S1–3).
The mRNAs in the HD fractions showed relatively low correla-
tion with the cellular mRNA, while LD mRNA showed a higher
correlation with the cellular RNA (Fig. 1E; Pearson’s correla-
tion r D 0.42 and r D 0.91, respectively). The most abundant
mRNAs in the cells and the LD fractions were transcripts for
several 40S and 60S ribosomal proteins, glyceraldehyde-3-phos-
phate dehydrogenase, a-enolase, and ubiquitin, while the most
abundant transcripts in the HD fractions were those for poly-
peptide N-acetylgalactosaminyltransferase-like protein 2 and
FK506-binding protein 14 (Table S1–3). Furthermore, the rela-
tionship between the mRNA in the HD and LD fractions was
relatively weak (Fig. 1E; Pearson’s correlation r D 0.57), which
suggests that the loading and release of mRNAs is different for
the structures found in the HD and LD fractions.
A total of 401, 369, and 490 miRNAs were reproducibly
identiﬁed in all HD, all LD, and all cellular samples, respectively
(Tables S4–6). In similarity with the mRNA analysis the miR-
NAs in the HD fractions showed relatively low correlation with
the cellular miRNA, while LD miRNA showed a higher correla-
tion with the cellular RNA (Fig. 1F; Pearson’s correlation r D
0.55 and r D 0.84, respectively). Even though the miRNAs in
the HD and LD samples correlated to some degree (Pearson’s
correlation r D 0.79), PCA showed that component 1 separates
the cells from the exRNA fractions, while component 2 sepa-
rates the HD fractions from the LD fractions (Fig. 1D and F).
We could observe 4 clusters (clusters 1–4) of mRNAs that
were more abundant in both the cells and the LD fractions, and
we found one cluster (cluster 5) that was more abundant in the
HD fractions (Fig. 1G). Cluster analysis of the miRNAs showed
4 clusters, one that contained miRNA that was abundant in
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Figure 1. Microarray analysis of the RNA content in the high- and low-density fractions. Isolated samples were allowed to ﬂoat into a sucrose gradient (0.4–2.5 M). High-
density extracellular RNA (HD exRNA) was isolated from fractions 8–10 of the ﬁltered sample, while low-density extracellular RNA (LD exRNA) was isolated from fractions
2–6 of the un-ﬁltered sample. (A and B) RNA was extracted from the HD and LD fractions, and the RNA proﬁles were analyzed with a Bioanalyzer instrument. (C and D)
HD and LD exRNA was analyzed for its mRNA and miRNA content with 3D Gene Microarray (Toray). Principal component analysis (PCA) was performed on the mRNA (C)
and miRNA (D) content. PCA was used to visualize the variance in RNA among samples from cells (blue), HD exRNA (red), and LD exRNA (green). (E and F) Scatter plots
were constructed to determine the relationship between mRNA (E) and miRNA (F) in the HD and LD exRNA with the cellular RNA. The correlation was determined with
the Pearson’s test (r D Pearson’s correlation). (G and H) Hierarchical clustering of the identiﬁed mRNA (G) and miRNA (H) in cells, HD fractions, and LD fractions (normal-
ized expression intensity is in log2 scale).
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both cells and LD fractions (cluster 3) and 3 clusters that were
uniquely up-regulated in the HD fractions (cluster 1), in the
LD fractions (cluster 2), or in cells (cluster 4; Fig. 1H). This
microarray analysis suggests that the HD and LD fractions con-
tain different structures that harbour fundamentally different
RNA cargo.
The exRNA in the high- and low-density fractions have
different non-coding RNA content as determined by NGS
In addition to the microarray, NGS was used to get a better
understanding of the RNAs that are not targeted by the probes
used in the arrays described above, including several ncRNA spe-
cies. To obtain high coverage, both a long (Nugen Ovation V2)
and a short (TruSeq small RNA by Illumina) RNA library was
constructed and sequenced for 2 replicates of RNA from the HD
and LD fractions as well as the RNA-producing cells. PCA
showed good reproducibility among the biological replicates
(Fig. S4A–B), and there were positive correlations in the RNA
expression between the biological replicates (Fig. S4C–D). In the
long RNA library, 0.8 £ 106 HD reads and approximately 10 £
106 LD and cellular reads were mapped to the human genome
after normalization. Coding reads were more abundant percent-
age-wise in the exRNA in the HD fraction than in the LD
exRNA (Fig. 2A and Table S7; 75% in the HD exRNA compared
to 20% in the LD exRNA). Furthermore, the mRNA in LD frac-
tions had a higher correlation with the cellular mRNA than the
HD mRNA did (Fig. 2B; blue box, Pearson’s correlation r D
0.92 and r D 0.60, respectively), while the mRNA in the HD
and LD fractions had relatively low correlation in the NGS anal-
ysis (Fig. 2B; green box, Pearson’s correlation r D 0.62). A total
of 13,567, 8971, and 11,353 mRNAs with a minimum of 10
reads were identiﬁed in both HD samples, both LD samples, or
both cellular samples, respectively (Tables S1–3). The non-coding
reads were percentage-wise more abundant in the exRNA from
the LD fractions than in the cells and the HD fractions (Fig. 2A
and Table S7; 80% compared to 55% and 25%, respectively).
When the ncRNAs were analyzed in detailed, most of the
ncRNA in the LD fraction and the cells consisted of mitochon-
drial rRNA, while long intergenic non-coding RNA (lincRNA)
and antisense RNA (Fig. 2A, Table 1 and Table S8) were the
most abundant in the HD exRNA. The lincRNA “nuclear para-
speckle assembly transcript 1” (NEAT1) and “metastasis associ-
ated lung adenocarcinoma transcript 1” (MALAT1) were present
in large amounts in all samples, while “long intergenic non-pro-
tein coding RNA 1206” and “long intergenic non-protein coding
RNA 910” were enriched in the HD fraction. The antisense
RNA “ZNFX1 antisense RNA 1” was highly expressed only in
the LD exRNA and cells, while “KCNQ1 opposite strand/anti-
sense transcript 1” was highly expressed in the HD exRNA and
cells.
Because the long RNA sample preparation creates libraries
with inserts longer than 200 nt, the short ncRNA classes would
not be sequenced using this method so a separate short library
was also constructed. In the short RNA library, 0.3 £ 106,
0.35 £ 106, and 0.55 £ 106 reads were mapped to the human
genome after normalization for the HD, LD, and cellular RNA,
respectively. The HD fraction contained mostly mature miRNA
(23%), while the LD fraction contained mainly tRNA (28%)
and mature miRNA (10%). Importantly, these proﬁles were
both different from the cells that produced these exRNAs. The
cells primarily contained mature miRNA (»55%) and snoRNA
(»3.5%) (Table 9). The exRNA in the HD fractions had more
reads mapped to mature miRNA, hairpin miRNA, vault RNA,
snoRNA, and small nuclear RNA (snRNA) (Fig. 3A–E,
Table S9, Table S10) in relation to the LD exRNA, while tRNA,
Figure 2. Next-generation sequencing analysis of the RNA content in the HD and LD fractions – long library. RNA was extracted from 2 biological replicates for the HD
and LD fractions as well as the exRNA producing cells, and the RNA was used to construct long RNA libraries (Nugen Ovation V2) that was sequenced. (A) The graph shows
the percentage of reads for each RNA biotype. (B) The correlation for the detected mRNA was determined with Pearson’s test. The correlation between the biological rep-
licates is indicated with red boxes, the correlation between the LD fractions or the HD fractions with the cellular mRNA is indicted with a blue box, and the correlation
between the HD and LD fractions is indicated with a green box.
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mitochondrial tRNA, piRNA, and Y RNA were most abundant
in the LD exRNA (Fig. 3F–I, Table S9, Table S10). A total of
199, 147, and 246 miRNAs were reproducibly identiﬁed with at
least 10 reads in both replicates of the HD, LD, or the cellular
samples, respectively (Tables S4–6).
The average lengths of the tRNA reads in both the HD and
LD exRNA were approximately 32 nucleotides (Fig. 4A–B)
indicating that the tRNAs are fragmented. tRNA fragments of
this size were also detected in the cells, but the cells also had
tRNA fragments with average lengths of approximately 17
nucleotides (Fig. 4C). Interestingly, 96% of the tRNA fragments
present in the LD exRNA were assigned to the 50 region
(Fig. 4D). Although cells contained fewer tRNA reads than the
LD exRNA, cells had more tRNA fragments assigned to the 30
region (Fig. 4D). The LD fractions and cells mainly contained
GluCTC tRNA, while the HD fractions primarily contained
GlyGCC tRNA. The cells showed a larger variation of tRNA;
while the HD and LD fractions contained 80% GluCTC, GlyGCC,
and ValCAC tRNAs, these 3 only made up 50% of the tRNAs in
cells (Fig. 4E).
Characteristics of the structures associated with the high-
and low-density exRNA
The RNA, protein, and particle concentrations were measured
for the HD and LD samples to calculate the amount of RNA
and protein per particle. As shown in Fig. 5A and B, the RNA
concentration was signiﬁcantly higher per particle in the HD
fraction than in the LD fraction (p < 0.01), whereas no signiﬁ-
cant difference was observed in protein concentration.
Furthermore, we analyzed the HD and LD fractions with
LC-MS/MS to investigate the proteins associated with the
exRNA. For the HD and LD fractions, 1436 and 2408 proteins
were identiﬁed, respectively (Table 11). The proteomes of both
HD and LD fractions were analyzed with Gene Ontology (GO)
Figure 3. Next-generation sequencing analysis of the RNA content in the HD and LD fractions – short library. RNA was extracted from 2 biological replicates for the HD
and LD fractions as well as the exRNA producing cells, and the RNA was used to construct short RNA libraries (TruSeq small RNA by Illumina) that was sequenced. The
graphs show the percentage of reads for each RNA biotype in each sample – (A) mature miRNA, (B) hairpin miRNA, (C) vault RNA, (D) snoRNA, (E) snRNA, (F) tRNA, (G)
mitochondrial tRNA, (H) piRNA, and (I) YRNA.
Table 1. Summary of the characteristics of the HD and LD fractions.
HD fractions LD fractions
Density 1.24–1.31 g/cm3 1.12–1.21 g/cm3
Peaks for 18S and 28S
rRNA
No Yes
Correlation with cellular
mRNA
No Yes
Main RNA biotypes
present
lincRNA, antisense RNA,
vault RNA, snoRNA,
snRNA, miRNA
Mitochondrial rRNA
and tRNA, tRNA, Y
RNA, piRNA,
miRNA
Associated cellular
compartments
with the protein
content
C Nucleus
C Ribosome
C Extracellular space
C Mitochondrion
C Endosome
C Plasma membrane
Size of associated
structures
51 § 0.7 nm 92 § 1.5 nm
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Term Finder to identify the associated functions that were most
enriched in relation to the genome frequency. “Protein bind-
ing,” “poly(A) RNA binding,” and “RNA binding” were the top
associated functions for the proteomes of both the HD and LD
fractions. Because the RNA contents of the HD and LD frac-
tions were substantially different, the RNA-binding proteins
are of special interest with 27% and 17% of the total proteins
being RNA-binding proteins in the HD and LD fractions,
respectively. Interestingly, 24% of the uniquely identiﬁed
RNA-binding proteins in the LD fractions were associated
with mitochondria, while none of the RNA-binding proteins
uniquely identiﬁed in the HD fractions or the RNA-binding
proteins identiﬁed in both HD and LD fractions were asso-
ciated with mitochondria. On the contrary, 68% of the
Figure 4. Analysis of tRNA fragments. (A–C) The graphs show the lengths of the tRNA reads identiﬁed in each sample, demonstrating an average length of »33 nucleoti-
des long fragments. (D) Each tRNA fragment (tRF) was assigned to the 50 region (blue), the 30 region (green), or as unknown (yellow). (E) The graphs show the percentage
of reads distributed in tRNA family type in all samples.
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RNA-binding proteins were associated with the nucleus in
the HD fractions compared with only 16% in the LD frac-
tions (Fig. 5C).
Additionally, the proteomes of both fractions were analyzed
to identify the associated cellular components. “Extracellular
vesicle,” “cytosol,” and “extracellular region” were among the
functions with the highest association for the proteomes of
both the HD and LD fractions. Because exRNAs are commonly
associated with EVs such as exosomes, the association with
“extracellular vesicle” was particularly interesting. Thus the HD
and LD fractions were analyzed with Western blot and ﬂow
cytometry for the presence of proteins that can be considered
to be enriched in exosomes and are commonly termed “exoso-
mal markers.”27 Western blot showed that TSG101 and CD81
were detected in both HD and LD fractions, while Annexin 2
and Flotillin 1 were mainly found only in the LD fraction
(Fig. 5D). Particles positive for 3 transmembrane proteins –
CD9, CD63 and CD81 – were also identiﬁed in both the HD
and LD fractions by ﬂow cytometry and anti-CD63 beads
(Fig. 5E).
Furthermore, 13 relevant Gene Ontology cellular compo-
nent terms were speciﬁcally chosen for comparison. For most
of the cellular components, the frequency was similar for the
proteins in the HD and LD fractions, with the exception of
“extracellular space,” “nucleus,” and “ribosome” that had a
higher frequency in the proteome of the HD fractions com-
pared to the LD proteome and “plasma membrane,” “mito-
chondrion,” and “endosome” that had a stronger association
with the proteome of the LD fractions compared to the HD
proteome (Fig. 5F).
Figure 5. Characterization of the exRNA-associated structures. (A and B) The number of particles was determined with nanoparticle tracking analysis (NTA) and used to
calculate the amount of RNA and protein per particle in the HD and LD fractions. Unpaired t-test;  p-value < 0.01. ns D non-signiﬁcant. (C) The proteomes of both the
HD and the LD fractions were analyzed with LC-MS/MS. In total, 1436 proteins were identiﬁed in the HD fractions and 2408 proteins in the LD fractions. Of these, 388 and
417, respectively, were categorized as “RNA-binding proteins” with Gene Ontology (GO). (D) The presence of the commonly used exosomal markers TSG101, CD81,
Annexin-2, and Flottilin-1 were determined with Western blot. (E) The presence of the tetraspanins CD9, CD63, and CD81 was determined by ﬂow cytometry with anti-
CD63-coated beads. (F) The total proteins identiﬁed with LC-MS/MS in the HD fractions (1436 proteins) and in the LD fractions (2408 proteins) were analyzed with GO
Term Finder to identify enriched cellular components compared to the genome frequency.
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Electron microscopy was used to further analyze the struc-
tures associated with HD and LD exRNA, and this revealed the
presence of vesicle-like structures in the LD fraction with an
average diameter of 92 nm, whereas the vesicle-like structures
in the HD fraction had an average diameter of 51 nm (Fig. 6A–
C, p < 0.0001). Immunogold staining could detect CD63 posi-
tivity in both the LD and HD fractions, but in both isolates the
CD63C structures were signiﬁcantly smaller than the CD63¡
structures (Fig. 6D; p < 0.05 and p < 0.001 for HD and LD,
respectively).
Discussion
This study demonstrates that a single cell type can release sev-
eral exRNA populations, as determined by both NGS and
microarray techniques. These exRNA signatures are present in
HD and LD extracellular fractions, which can be separated by
ﬂotation on a density gradient. Further, the RNA signatures are
associated with different proteins, as determined by mass spec-
trometry. Some of the RNA in both fractions might be carried
as cargo in EVs because electron microscopy reveals the pres-
ence of round CD63C structures in both fractions (Table 1
summarizes the characteristics of the HD and LD exRNA).
The clear lack of correlation between both the long and
short RNA in the HD and LD fractions as analyzed with both
microarray and NGS (Fig. 1E–F, Fig. 2B and Fig. S4C–D)
strongly argues that the exRNAs in the 2 fractions are associ-
ated with distinct pathways. This is further supported by the
PCA, which showed that both mRNA and miRNA cluster dif-
ferently in whole cells and in the HD vs. LD fractions (Fig. 1C
and D and Fig. S4A and B). For mRNA, there is a low correla-
tion between the cells and the HD exRNA, but a good correla-
tion between the cells and the LD exRNA, in the microarray
analysis (Fig. 1E). This conclusion is supported by similar data
acquired by NGS (Fig. 2B). Our current data might indeed
explain several observations made in the literature regarding
exRNA. Several studies have demonstrated a limited relation-
ship between cellular and extracellular mRNA when analyzing
exRNA in EVs20,28,29, while other studies have suggested a
closer relationship between cellular and extracellular mRNA in
vesicles.30,31 Similarly, several studies have observed a lack of
peaks for the full-length 18S and 28S rRNA subunits when ana-
lyzing exRNA in EVs.20,28,32-36 In contrast, other studies have
identiﬁed peaks for 18S and 28S rRNA in EV-associated
exRNA.30,33,37 The differences in these previous studies might
be explained in part by cell or tissue-speciﬁc differences, differ-
ent isolation methods, and/or the use of different RNA analysis
Figure 6. Electron microscopy analysis of exRNA-associated structures. Samples (10 mg protein) were loaded onto grids, labeled with anti-CD63, and examined by elec-
tron microscopy. (A) All structures in approximately 100 micrographs per sample type were measured and are presented as graphs with the number of structures on the
y-axis and the diameter of the structures in nm on the x-axis. In total, the diameters of 1566 structures were measured for this analysis (425 and 1141 for the HD and LD
fractions, respectively). (B) The structures in the LD fractions were signiﬁcantly larger (92 § 1.5 nm) than the HD structures (51 § 0.7 nm). (C) Representative electron
micrographs are shown for each separated fraction. (D) In both the HD and LD fractions, the CD63C structures were smaller than the CD63¡ structures. Unpaired t-test; 
p< 0.05,  p < 0.001,  p < 0.0001.
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platforms. However, our current results strongly suggest that
different exRNAs are present in the extracellular space (Fig. 1A
and B) and they may be enriched by different isolation meth-
ods, which can affect the results and can thus explain the previ-
ously contradictory ﬁndings.20,28-31 It is clear that exRNA
represents several entities, but it is also possible that the HD
and LD fractions themselves are mixtures of multiple exRNA-
containing structures that come together in the same density
fractions. Special steps are clearly required to fully separate dis-
tinct exRNA proﬁles, which is important to understanding the
differences in their biology.
The exRNA in the HD fractions consisted mainly of mRNA,
miRNA, lincRNA, antisense RNA, vault RNA, snoRNA, and
snRNA, while the LD exRNA consisted mainly of mRNA,
miRNA, mitochondrial rRNA, mitochondrial tRNA, tRNA,
piRNA, and Y RNA (Figs. 2 and 3). Y RNA is a family of 84–
113 nt hairpin-containing ncRNAs that are involved in Ro60
inhibition and DNA replication initiation.38 Y RNA has been
suggested to be associated with EVs,21 however there are also
reports indicating that Y RNA does not circulate in vesicles but
in protein complexes with a mass of 100 or 300 kDa.39 One
study demonstrated that Y RNA is enriched in EVs compared
to the EV-producing cells.40 However, we observed no enrich-
ment in Y RNA in the HD and LD fractions compared to cellu-
lar RNA. It has also previously been shown that when dendritic
cells and T cells are co-cultured the extracellular Y RNA
released is mainly associated with the LD fractions and not the
HD fractions,21 which is in line with our results in which more
Y RNA was associated with the particles in the LD fractions
than the HD fractions (Fig. 3I).
Vaults are large ribonucleoprotein particles located in the
cytoplasm that consist of one major vault protein (MVP), 2
minor vault proteins (VPARP and TEP1), and 80–150 nt vault
RNAs.41 We report here that the vault RNA was exclusively
detected in the HD fractions (Fig. 3C). Furthermore, all 3 vault
proteins (MVP, VPARP, and TEP1) were exclusively detected
in the HD fractions in the mass spectrometry analysis
(Table S11). Vaults are visible in electron microscopy with a
characteristic form,42 however we saw no evidence of whole
complexes in the negative stain that we performed (Fig. 6C).
Vault RNA has previously been detected in EVs21,43 and at the
time was hypothesized to play a role in the sorting of RNAs
into the vesicles.21 It can only be speculated upon as to whether
the vault RNA detected here plays any part in sorting RNA
into the HD structures, but it is worth noting that the HD
exRNA correlated to a lesser degree with the cellular RNA com-
pared with the LD exRNA (Fig. 1E and Fig. 2B).
tRNAs are 76–90 nt ncRNAs that take part in translation by
transporting amino acids to the protein synthesis machinery. It
has recently been suggested that tRNAs can also be processed
into fragments that have modulatory effects.44 We observed
that cellular RNA contained fragments of 2 sizes, »17 and
»33 nt, while the exRNA in the HD and LD fractions only con-
tained the 33 nt fragments (Fig. 4A-C). We found that both LD
and HD exRNA, but in particular LD exRNA, almost exclu-
sively contained tRNA fragments originating from the 50 end
(Fig. 4D). The cellular RNA also contained more 50 end tRNA,
however it also contained 30 end tRNA fragments. This is in
agreement with previous reports in which the tRNA fragments
detected extracellularly in EVs from human semen and
immune cells are also primarily derived from the 50 end.21,45,46
We observed that HD and LD exRNA mainly contained
GlyGCC and GluCTC tRNA, while the cells had a larger variation
in tRNAs (Fig. 4E), which conﬁrmed previous ﬁndings of extra-
cellular tRNA in EVs.45
tRNA fragments can arise through 2 main processes. The
ﬁrst is stressed-induced tRNA cleavage47, which is angiogenin-
dependent and leads to cleavage of the tRNAs at the anti-codon
loop. The second is the inability of the reverse transcriptase to
process cDNA of the entire tRNA due to the presence of post-
transcriptional modiﬁcations (such as methylation) that hinder
efﬁcient sequencing by NGS. The tRNA fragments for both the
cells and exRNA were mostly 32–34 bases long and terminated
at the anticodon loop of the tRNA. Furthermore, the 2 most
highly abundant tRNA fragment species, GluCTC and GlyGCC,
that make up close to 70% of the tRNA fragments seen in the
exRNA and »45% of the tRNA fragments seen in the cells have
no methylation modiﬁcation at the anticodon loop. This sug-
gests that the tRNA fragments that were identiﬁed here are due
to cleavage rather than incomplete sequencing due to post-
transcriptional tRNA modiﬁcations.
snRNA is a class of approximately 150 nt RNA molecules,
commonly called U-RNA. Together with several speciﬁc
proteins, snRNA forms complexes called small nuclear ribonu-
cleoproteins (snRNPs) that participate in the splicing of pre-
mRNA. snoRNAs are a class of small RNA molecules that
primarily guide chemical modiﬁcations (methylation and pseu-
douridylation) of other RNAs, such as rRNAs and tRNAs. Both
snRNAs and snoRNAs were enriched in the exRNA in the HD
fractions and the cells compared to the LD exRNA (Fig. 3D
and E). Both of these RNA classes are located in the nucleus,
and, interestingly, the HD proteome was more strongly associ-
ated with the nucleus than the LD proteome (Fig. 5F). On the
contrary, both the RNA and the proteins in the LD fractions
were highly associated with the mitochondria compared to the
HD fractions (Fig. 2A, 3G, 5C and 5F). Because some NGS
studies on exRNA in EVs have focused primarily on the
miRNA48 or only on RNA shorter than 70–100 nt,21,46 they
might have missed the mitochondrial RNA that we have
detected here (Fig. 2A and 3G). There are studies that have
identiﬁed mitochondrial RNA in exRNA in EVs,22,40 and these
showed that the mitochondrial RNA was enriched in EV popu-
lations that contained rRNA peaks, but not in the EV subpopu-
lations that did not contain rRNA peaks.22 This indicates an
association with the mitochondria for the rRNA-containing
structures in the LD fractions. In addition to the association
with the nucleus, the proteome of the HD fraction was also
associated with the ribosome. This was unexpected given that
the exRNA proﬁle in the HD fraction did not show any indica-
tion of full-length 18S and 28S rRNA peaks but still seems to
have a proteome associated with ribosomes. Because both the RNA
and protein associated with the structures identiﬁed in the HD and
LD fractions are dissimilar, it is unlikely that they have evolved
from a common pathway and by chance ended up having slightly
different densities and/or cargos. This suggests that the HD and
LD exRNA are derived fromdifferent biogenesis pathways. Overall,
based on the proteomics it seems plausible that the HD exRNA
production, at least to some degree, is associated with the nucleus,
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whereas the LD exRNA might be more associated with the cell
membrane andmitochondria.
We demonstrate by mass spectrometry and Western blot
that both the HD and LD exRNA proﬁles are associated with
structures that are positive for several commonly used exoso-
mal markers. This is intriguing because both the RNA and pro-
tein content are substantially different in the HD and LD
fractions, which suggests that the HD and LD exRNA are
derived from different biogenesis pathways. Although ﬂow
cytometry demonstrates the presence of tetraspanins, which
could suggestion the presence of a lipid bilayer, the experimen-
tal approach applied here cannot distinguish the exact molecu-
lar and/or vesicular structures with which the exRNA is
associated. Electron microscopy suggests that at least a part of
the exRNA could be associated with extracellular vesicle-like
structures (Fig. 6C).
It is possible that exRNAs and their associated extracellular
vesicle-like structures, when released by other cells or under
other conditions, may behave differently during the ultracentri-
fugation procedure and end up in different pellets compared to
our study. Importantly, if a swinging bucket rotor is used all
material will be pelleted at the bottom as one pellet. However,
we have loaded both pellets on the same density gradient and
the HD and LD exRNA was successfully separated then as well
(data not shown). We therefore suggest that one density gradi-
ent can separate these 2 exRNA entities also when they have
been co-isolated.
To further elucidate the biogenesis and function of subpopu-
lations of exRNA released by a single type of cell, it is crucial to
describe their molecular contents and to develop methodolo-
gies to separate them efﬁciently. The fact that several proteins
that are associated with the HD and LD exRNA are differen-
tially expressed suggests that the HD and LD exRNA are
derived from different biogenesis pathways, which might also
provide clues to developing exRNA subtype-speciﬁc markers.
This study therefore describes a fundamental advance in the
study of exRNA. However, our study also introduces another
level of complexity to the ﬁeld, and any study of exRNA must
now consider the possibility that it could be studying a single
subpopulation or a mixture of several subpopulations. Addi-
tionally, from a clinical perspective it is possible that RNA-
based biomarkers for any disease might lie with separate subpo-
pulations of structures, which is necessary to consider in the
course of disease biomarker discovery.
Material and methods
Cells
The human mast cell line HMC-1 (Dr. Joseph Butterﬁeld,
Mayo Clinic, Rochester, MN, USA) and the erythroleukemic
cell line TF-1 (ATCC: CRL-2003) were cultured in a 37C
humidiﬁed incubator with 5% CO2. HMC-1 was cultured in
Iscove’s Modiﬁed Dulbecco’s Medium (IMDM), while TF-1
was cultured in RPMI-1640. Both media were supplemented
with 10% foetal bovine serum (FBS), 100 units/ml penicillin,
100 mg/ml streptomycin, and 2 mM L-glutamine. In addition,
the medium for HMC-1 also contained 1.2 mM a-thioglycerol
and the medium for TF-1 was supplemented with 5 ng/mL
granulocyte macrophage colony-stimulating factor (GM-CSF)
(all reagents were from Sigma-Aldrich, St Louis, MO, USA).
To eliminate serum exosomes, the FBS was ultracentrifuged
(Ti45 rotor, Beckman Coulter, Brea, CA, USA) for 18 hours at
120,000 £ g (average) prior to use in cultures.
The cell viability was calculated using the trypan blue dye
method.
Isolation of exRNA-enriched isolates
ExRNA-enriched isolates were isolated from fresh conditioned
media from HMC-1 and TF-1 cell cultures. Cells, debris, and
large extracellular vesicles were eliminated by centrifugation at
300 £ g for 10 minutes and at 16,500 £ g for 20 minutes. Only
half of the supernatant was passed through 0.2 mm ﬁlters
(Sarstedt, N€umbrecht-Rommelsdorf, Germany), whereas the
other half was left unﬁltered prior to the last ultracentrifugation
step at 120,000 £ g for 70 minutes (average Ti45 rotor: ﬁxed
angle rotor). In the samples isolated without the ﬁltration step,
2 separate pellets could be identiﬁed; one pellet that was ﬁrmly
attached to the tube wall (pellet 1), and a second non-adherent
pellet (pellet 2) at the bottom of the tube (schematics are shown
in Fig. S1A). Pellet 1 was also found in the ﬁltered samples,
whereas pellet 2 (the non-adherent) was never observed in the
isolation where the 0.2 mm ﬁltration step was applied. Because
pellet 2 would normally be discarded in the supernatant
removal steps, pellet 2 were collected using a pipette before the
medium was poured off, while pellet 1 were collected after the
medium was poured off by resuspension of the pellets in an
appropriate buffer.
Separation of exRNA on sucrose gradients
Further isolation of the different subpopulations of exRNA was
performed using sucrose gradients. Pellet 1 and pellet 2 were
layered at the bottom of a sucrose gradient, and 10 fractions
were isolated and re-pelleted for further analyses. The sucrose
gradient procedure was performed as previously described49.
Brieﬂy, for the bottom-loaded gradients, isolated pellets were
resuspended in 2.5 M sucrose in PBS and transferred to an
ultracentrifuge tube. Fifteen consecutive 2.2 ml layers of
decreasing sucrose concentrations in PBS (from 2 M to 0.4 M)
were layered on top of the sample. For the top-loaded gradients,
15 consecutive 2.2 ml layers of decreasing sucrose concentra-
tions in PBS (from 2.5 M to 0.5 M) were layered in an ultracen-
trifuge tube. Isolated pellets were then resuspended in 0.4 M
sucrose in PBS and layered on top of the gradient. Gradients
were ultracentrifuged for 16 hours, without the applications of
brakes, at 4C in a SW32 rotor (swinging bucket rotor) at
175,000 £ g (maximum). Ten fractions were collected (3.9 ml
each), and the density of the sucrose was measured with a
refractometer. Fractions were diluted in PBS separately or
pooled (fractions 2–6 or 8–10) and ultracentrifuged at 120,000
£ g (Ti70 rotor).
RNA isolation
The RNA was isolated with the miRCURY
TM
RNA Isolation
Kit - Cell and Plant (Exiqon A/S, Vedbaek, Denmark)
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according to the manufacturer’s protocol (with 1% 2-mercap-
toethanol in the lysis buffer) and analyzed on an RNA 6000
Nano chip or an RNA 6000 Pico chip using an Agilent 2100
Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA)
according to the manufacturer’s protocol.
Microarray
For the miRNA analysis, all samples were mixed with miRNA
spike (Toray Industries Inc., Tokyo, Japan) and further labeled,
hybridized, and washed according to the manufacture’s proto-
col (3DGENE miRNA label Hybridization 4plex v1, Toray
Industries Inc.) using the miRCURY LNA microRNA Array
Power Labeling kit (Exiqon) and Human miRNA Oligo chip –
4plex (Toray Industries Inc.). The intensity of each miRNA
was analyzed with the 3D-Gene Scanner 3000 (Toray Industries
Inc.) with auto gain, auto focus, and auto analysis settings.
Quality control was performed on all samples based on the
quality-control report from the instrument.
For the mRNA analysis, the mRNA was converted into
aRNA according to the manufacture’s protocol (3DGENE
mRNA ampliﬁcation v2, Toray Industries Inc.) using the
Amino Allyl MessageAmpTM II aRNA Ampliﬁcation Kit (Life
Technologies) and analyzed for size distribution using gel elec-
trophoresis (Bio-Rad laboratories). The aRNA was then labeled
with Cy5 Mono-Reactive Dye (GE Healthcare, Little Chalfont,
UK) and puriﬁed using columns (Bio-Rad and Millipore,
Billerica, MA, USA) according to the manufacture’s protocol
(3DGENE mRNA CyDye label v2, Toray Industries Inc.).
Incorporation of Cy5 and the concentration of the labeled
aRNA was determined on a NanoDrop 1000 spectrophotome-
ter (Thermo Fisher Scientiﬁc) before being hybridized to
microarray chips (Human Oligo Chip 25k ver. 2.1., Toray
Industries Inc.). The hybridization and subsequent washing
was performed according to the manufacture’s protocol
(3DGENE mRNA hybridization v2, Toray Industries Inc.). The
intensity of each mRNA was analyzed with the 3D-Gene Scan-
ner 3000 (Toray Industries Inc.) with auto gain, auto focus or
focus set to zero, and auto analysis settings. Quality control was
performed on all 10 samples based on the quality-control
report from the instrument.
Normalization of microarrays
RNA expression in each dataset was normalized by quantile
normalization50 with MATLAB (version 2010a). Fold changes
(log2-ratio) were also calculated by MATLAB (version 2010a).
To deﬁne HD and LD mRNA and miRNA based on the ﬂuo-
rescence value of microarray, we used the previous method
using Gaussian mixture model.30,51,52 Using false discovery of
<1%, we deﬁned mRNA and miRNA whose ﬂuorescence val-
ues are over 5.8515 and 6.7554, as present mRNA and miRNA,
respectively.
To choose the high-quality data sets to be used in further
analyses, quality control was performed not only by depicting
the scatter plots of relative RNA expression, but also by per-
forming principal component analysis (PCA),53 which is pro-
vided by MATLAB (version 2010a).
Next-generation sequencing
For both the whole transcriptome and small-RNA sequencing,
the raw sequence image ﬁles from the Illumina HiSeq 2500
were converted to the fastq format and checked to ensure that
the quality scores did not deteriorate drastically at the read
ends. The fastqs were trimmed to remove the adapters for the
small-RNA sequencing runs whereas for the long RNA they
were left untrimmed. The fastqs were then aligned to the refer-
ence human genome (hg19, Ensembl version 75) using STAR
v2.4.0 for the long RNA and Bowtie for the small RNA. STAR
also aligned the reads to a splice junction database to annotate
splice junctions between exons. The STAR/Bowtie-aligned .sam
ﬁles were converted to .bam ﬁles and sorted by coordinate posi-
tion using SAMtools v0.1.19.
For the whole-transcriptome sequencing runs, read counts
for genes were generated using featureCounts with hg19,
Ensembl 75 as the gene reference. The libraries for the samples
were scaled to the total number of reads mapping to the refer-
ence human genome (total library normalization).
For the small-RNA sequencing runs, the samples were run
through sRNAbench, which allows one to map the reads to var-
ious other RNA libraries using Bowtie. The reads mapping to
rRNA (from NCBI) were removed, and the remaining reads
were mapped to the miRNA database (miRBase v21). After
mapping to miRNA, the remaining reads were simultaneously
and competitively mapped to the other RNA libraries, namely,
tRNA (from UCSC http://gtrnadb.ucsc.edu/Hsapi19/hg19-
tRNAs.fa), piRNA (piRBase v1.0), and all other genes found in
the Ensembl 75 gtf.
No threshold was used for the correlations and all genes
were used irrespective of their expression. The detected RNA
threshold was set to >10 reads for all RNA.
Protein concentration
The protein concentrations of the various samples were deter-
mined using the Pierce BCA Protein assay kit (Thermo Fisher
Scientiﬁc, Waltham, MA, USA) according to the manufac-
turer’s protocol.
Nanoparticle tracking analysis (NTA)
NTA measurements were performed with a NanoSight LM10
(NanoSight, Amesbury, UK) equipped with a 0.3 ml sample
chamber and a 640 nm laser. All measurements were per-
formed at room temperature. Furthermore, the temperature
was measured for each analysis and manually entered into the
system. The software used for capturing and analyzing the data
was NTA 2.2 Build 0381. For all samples, 0.5 mg protein was
resuspended in 1 ml of 0.1 mm ﬁltered PBS. Each sample was
measured 5 £ 60 seconds, and for each of these measurements
a new portion of the sample was injected. The result for each
sample is presented as an average of the 5 measurements. The
camera settings were as follows: camera shutter D 1472 and
camera gain D 509. The analysis settings were as follows: detec-
tion threshold D auto, blur D 5 £ 5, minimum track length D
auto, and minimum expected particle size D 30 nm.
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Sample preparation for protein extraction and digestion
HD and LD fractions were initially lysed in 8 M urea, 50 mM
triethylammonium bicarbonate (TEAB) buffer pH 8.5, 4% 3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), 0.2% sodium dodecyl sulfate (SDS), and 5 mM
EDTA. The remaining pellet was further solubilised with
250 mM TEAB, 4% SDS, and 300 mM dithiothreitol (DTT) pH
7.6. The protein concentration was determined using the Pierce
660 nm Protein Assay Reagent (Thermo Fisher Scientiﬁc), and
1000 mg per sample was used for further analysis.
Each sample was incubated with tris(2-carboxyethyl)phos-
phine (TCEP), transferred to 3K MW cutoff ﬁlters (Pall) and
diluted with 8 M urea in 0.1 M TEAB for ﬁlter-aided sample
preparation (FASP)54. Samples were alkylated with methyl
methanethiosulfonate (MMTS) and digested with trypsin in
0.5 M TEAB at a 1:25 ratio overnight at 37C. The peptides
were eluted at 12,000 rpm for 10 minutes, and ﬁlters were
rinsed with 20% acetonitrile (ACN) at 12,000 rpm for
5 minutes.
Strong cation exchange chromatography (SCX) of peptides
The concentrated peptides were acidiﬁed with 10% formic acid
(FA) and diluted with SCX solvent A (25 mM ammonium for-
mate pH 2.8, 20% ACN) and injected onto a PolySUL-
FOETHYL A SCX column (2.1 mm i.d. £ 10 cm length, 5 mm
particle size, 300 A

pore size). SCX chromatography and frac-
tionation were carried out on an €AKTA puriﬁer system (GE
Healthcare) at a 0.25 mL/minute ﬂow rate using the following
gradient: 0% B (500 mM ammonium formate pH 2.8, 20%
ACN) for 5 minutes; 0–40% B for 20 minutes; 40–100% B for
10 minutes; and 100% B for 10 minutes. UV absorbance at
254 nm and 280 nm was monitored while fractions were col-
lected at 0.5 mL intervals. The fraction volumes were reduced
in a SpeedVac. The 20 peptide-containing fractions were
desalted on PepClean C18 spin columns according to the man-
ufacturer’s instructions (Thermo Fisher Scientiﬁc).
NanoLC-MS/MS analysis on an LTQ-Orbitrap Velos
instrument
The desalted and dried fractions were reconstituted in 0.1% FA
and analyzed on an LTQ-Orbitrap Velos (Thermo Fisher Scien-
tiﬁc) interfaced with an in-house constructed nano-LC col-
umn55. Two-microlitre sample injections were made with an
Easy-nLC autosampler (Thermo Fisher Scientiﬁc) running at
200 nL/minute. The peptides were trapped on a pre-column
(45 £ 0.075 mm i.d.) and separated on a reversed phase col-
umn, 200 £ 0.075 mm packed with 3 mm Reprosil-Pur C18-
AQ particles. The gradient was as follows: 0–70 minutes 5–25%
ACN, 0.2% FA; 70–80 minutes 25–40% ACN, 0.2% FA80%
ACN, 0.2% FA over 5 minutes and held for the last 10 minutes
at 80% ACN, 0.1% FA.
The LTQ-Orbitrap Velos settings were a: spray voltage
1.6kV, 1 microscan for MS1 scans at 60,000 resolution (m/z
400), and a full MS mass range m/z 400–1800. The LTQ-Orbi-
trap Velos was operated in a data-dependent mode with one
MS1 FTMS precursor ion scan followed by CID (collision-
induced dissociation) MS2 scans of the 10 most abundant dou-
bly or multiply protonated ions in each FTMS scan. Dynamic
exclusion within 20 ppm for 30 seconds was used after 2 repeats
of MS2 for a precursor ion. MS2 were collected with 1 micro-
scan and a collision energy of 35%.
Database search and quantiﬁcation of proteomic data
We performed peptide identiﬁcation using X! Tandem incor-
porated in a trans-proteomic pipeline (version 4.6 OCCUPY
rev 2).56 Each RAW data ﬁle was ﬁrst converted to mzXML
using the msconvert tool incorporated in ProteoWizard (ver-
sion 3.0.4205).57 MS/MS scans in the converted mzXMLs were
then searched in X!! Tandem against the Homo sapiens Swiss-
Prot database (release 2013 08) containing 20,272 proteins. The
tolerance was set to 10 ppm for precursor ions and 0.8 Da for
fragment ions. Enzyme speciﬁcity for trypsin was used. Vari-
able modiﬁcation options were used for the oxidation of methi-
onine (15.995 Da), carbamidomethylation of cysteine (57.021
Da), deamination of N-terminal glutamine (¡17.027 Da), and
dehydration of N-terminal glutamic acid (¡18.011 Da). The
number of missed cleavage sites was set to be two. We ﬁnally
used TPP to statistically identify peptides from the X!! Tandem
search results by PeptideProphet (PeptideProphet  0.90) and
then proteins using ProteinProphet (ProteinProphet  0.90).
When multiple proteins were assigned to a protein group, we
selected the representative protein with the highest coverage.
To measure the quantity of each protein in our density fraction
proteomes, we calculated relative protein abundance using
absolute protein expression (APEX)58. The APEX quantiﬁca-
tion is based on spectral counting of each protein corrected by
prior expectation of observing each peptide. The ﬁrst 50 top-
ranked proteins with high spectral counts from the ProteinPro-
phet results were selected as a training dataset in order to gen-
erate an experiment-speciﬁc data set. With APEX
normalization factor D 10,000, the protein abundance was then
calculated as described in Braisted et al.59.
Bioinformatic analysis
The proteins identiﬁed with LC-MS/MS were analyzed using
the Gene Ontology (GO) Term Finder software (http://go.
princeton.edu/cgi-bin/GOTermFinder)60, the Human Protein
Atlas (http://www.proteinatlas.org/), and the database for
annotation, visualization and integrated discovery (DAVID;
http://david.abcc.ncifcrf.gov/). DAVID was also used to analyze
the identiﬁed mRNAs, while miRSystem was used to analyze
the identiﬁed miRNAs. These commercially available databases
and software identify cellular components, biological functions,
biological processes, pathways, and networks associated or
enriched in protein, mRNA, and miRNA datasets, and they
also identify the cellular location of the identiﬁed protein.
Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html)
was used to compare lists of proteins to ﬁnd common and
unique molecules61.
To catalog molecules, hierarchical clustering analysis62 was
performed on the normalized expression intensities. The
expression intensities for each molecule were normalized to
have a mean of 0 and a standard deviation of 1. For hierarchical
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clustering analysis and normalization, the “Clustergram” func-
tion in MATLAB (version 2010a) was used with the following
parameters: linkage D ward; clustering D rows and columns;
and distance function D euclidean.
Data access
The complete MS proteomics data were deposited to the PRote-
omics IDEntiﬁcations database (PRIDE) of the European
Molecular Biology Laboratory - European Bioinformatics Insti-
tute (EMBL-EBI) under the set identiﬁer PXD004931. The raw
reads for the NGS were deposited to the Sequence Read Archive
(SRA) of the National Center for Biotechnology Information
(NCBI) under bioproject ID PRJNA343960. (http://www.ncbi.
nlm.nih.gov/bioproject/343960). The microarray gene expres-
sion data were deposited in NCBI's Gene Expression Omnibus
(GEO) under the GEO Series accession number GSE88755.
Western blot
Proteins were extracted from cells and HD and LD isolates by
dissolving the samples in RIPA buffer and sonicating them 3 £
5 minutes with vortex mixing in-between. Thirty micrograms
of proteins were loaded per well and separated on precast gels
(Mini-PROTEAN TGX Gels; Bio-Rad laboratories, Hercules,
CA, USA) and transferred to nitrocellulose membranes (Bio-
Rad laboratories). The membranes were blocked with 5% Blot-
ting Grade Blocker Non-Fat Dry Milk (Bio-Rad Laboratories)
in TBST for one hour prior to incubation with anti-Flotillin-1
(1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA),
anti-CD81 (1:800 dilution, Santa Cruz Biotechnology), anti-
TSG101 (1:1000 dilution, Abcam, Cambridge, UK), or anti-
Annexin-2 (1:1000 dilution, Abcam). All primary antibodies
were diluted in 0.25% Blotting Grade Blocker Non-Fat Dry
Milk in TBST and incubated with the membrane overnight at
4C. The membranes were washed 3 times before incubation
with the secondary antibody for one hour. Secondary antibod-
ies were goat F(ab’)2 anti-rabbit IgG (horseradish peroxidase
conjugated) for Flotillin-1, CD81, and Annexin-2 (1:5000 dilu-
tion) (Harlan Sera-Lab, Loughborough, UK) and sheep anti-
mouse Ig (horseradish peroxidase conjugated F(ab’)2) for
Tsg101 (1:5000 dilution; GE Healthcare, Uppsala, Sweden)
diluted in 0.25% Blotting Grade Blocker Non-Fat Dry Milk in
TBST. The membrane was then analyzed with the Amersham
ECL Prime Western Blotting Detection System (GE Health-
care) and a VersaDoc 4000 MP (Bio-Rad Laboratories).
Flow cytometry
Isolated HD and LD samples resuspended in PBS were incu-
bated with anti-CD63-coated beads (15 mg sample/70,000
beads for each antibody; Life Technologies, Carlsbad, CA,
USA) overnight at 4C with gentle agitation. The sample-bead
complexes were washed 3 times with 1% exosome-depleted
FBS in PBS, incubated with human IgG (Sigma-Aldrich) for
15 minutes at 4C, washed 3 times, and incubated with PE-
labeled anti-CD9, anti-CD63, anti-CD81, or the appropriate
isotype control for 40 minutes at room temperature (all anti-
bodies were from BD Bioscience, San Jose, CA, USA). The
samples were washed 2 times before 10,000 events were
acquired in a FACSAria (BD Bioscience) and analyzed using
the FlowJo Software (Tri Star Inc., Ashland, OR, USA).
Electron microscopy
Formvar/carbon-coated nickel grids (Ted Pella, Inc., Redding,
CA, USA) were UV-treated for 5 minutes before 10 mg of sam-
ple was loaded. The grids and samples were incubated for
10 minutes before being ﬁxed in 2% paraformaldehyde. Sam-
ples were immunostained with anti-CD63 antibody (BD Biosci-
ence) or an appropriate isotype control (Sigma-Aldrich). Gold-
labeled secondary antibody was added before the samples were
ﬁxed in 2.5% glutaraldehyde and contrasted in 2% uranyl ace-
tate. The preparations were examined using a LEO 912AB
Omega electron microscope (Carl Zeiss NTS, Jena, Germany).
Vesicles were measured with the iTEM software (Olympus-
SiS, M€unster, Germany).
Statistical analysis
Where appropriate, data are expressed as mean § SEM. Statis-
tical analysis was performed by paired or non-paired Student’s
t-test in GraphPad Prism 6 (GraphPad Software Inc., La Jolla,
CA, USA).
The correlations of expression were veriﬁed by Pearson’s63
test calculated by MATLAB (version 2010a). If the correlation
coefﬁcient r was over 0.9, we deﬁned the correlation as high.
The existence of a correlation existence was regarded as conﬁ-
dent if p-values were less than 0.001.
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